EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Chronic viral hepatitis with concurrent metabolic dysfunction-associated steatotic liver disease: dual etiology challenges

Shang-Chin Huang, Yi-Fen Shih, Chun-Jen Liu

Clinical and Molecular Hepatology · 30.09.2026 · 32 (Suppl) · e2026.0387

DOI: 10.3350/cmh.2026.0387 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 30.09.2026. Verfasst von Shang-Chin Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan. Hauptthemen laut MEDLINE: Fatty Liver, Hepatitis C, Chronic, Hepatitis B, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The overlapping epidemics of chronic viral hepatitis and metabolic dysfunction-associated steatotic liver disease (MASLD) present a complex challenge in modern hepatology. In chronic hepatitis B, a unique “steatosis paradox” emerges: while isolated hepatic steatosis provides a suppressive microenvironment that promotes hepatitis B viral clearance, the concomitant systemic cardiometabolic burden acts dose-dependently to drive fibrogenesis and hepatocellular carcinoma (HCC). Conversely, chronic hepatitis C and host metabolic dysfunctions exhibit synergistic destruction. Hepatitis C virus actively hijacks lipid metabolism and induces insulin resistance. Even after viral eradication via direct-acting antivirals, residual steatosis and glycemic abnormalities remain formidable drivers of HCC. Consequently, the traditional virocentric paradigm is no longer sufficient. Clinical management should pivot toward precision risk stratification and a multidisciplinary dual-target approach, equally prioritizing sustained viral suppression and aggressive metabolic remission. This review summarizes the divergent virus-MASLD interactions, optimal clinical strategies, current challenges and future opportunities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverHepatitis C, ChronicHepatitis B, ChronicHumansLiver NeoplasmsCarcinoma, HepatocellularAntiviral AgentsInsulin ResistanceHepatitis B virusNon-alcoholic Fatty Liver DiseaseLipid MetabolismHepacivirus

Stichwörter der Autor:innen

Chronic hepatitisFatty liverHepatitis B virusHepatitis CNon-alcoholic fatty liver disease

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Physical Therapy and Assistive Technology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. cjliu@ntu.edu.tw.

Zitieren

APA

Huang, S. C., Shih, Y. F., & Liu, C. J. (2026). Chronic viral hepatitis with concurrent metabolic dysfunction-associated steatotic liver disease: dual etiology challenges. Clinical and Molecular Hepatology, 32(Suppl), e2026.0387. https://doi.org/10.3350/cmh.2026.0387

Vancouver

Huang SC, Shih YF, Liu CJ. Chronic viral hepatitis with concurrent metabolic dysfunction-associated steatotic liver disease: dual etiology challenges. Clinical and Molecular Hepatology. 2026;32(Suppl):e2026.0387. doi:10.3350/cmh.2026.0387

BibTeX
@article{Huang2026,
  author = {Huang, Shang-Chin and Shih, Yi-Fen and Liu, Chun-Jen},
  title = {Chronic viral hepatitis with concurrent metabolic dysfunction-associated steatotic liver disease: dual etiology challenges},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {Suppl},
  pages = {e2026.0387},
  doi = {10.3350/cmh.2026.0387}
}
Kostenlos starten →